Early clinical case studies

CardioResearch and ICON partnered to deliver a complex phase 1b–2a heart failure trial through collaborative expertise, governance, and innovative operational execution.

ICON partnered with the University Medical Center Groningen to execute a demanding cross over study requiring 240 brain MRI scans in 60 healthy participants. Through an integrated clinical and imaging solution, strong operational coordination, and a long standing academic partnership, ICON enabled accelerated execution, data consistency, and a seamless participant experience, demonstrating how innovative early phase delivery models can overcome complexity and support urgent development priorities.

This phase 1 oncology ADME and ABA study faced strict eligibility, screening, radiolabeled drug logistics, and 72-hour shelf-life constraints, requiring precise coordination, specialised expertise and patient recruitment.

Successful 3-arm, double-blind study on a denosumab biosimilar in 225 healthy men over 10 months at two ICON sites.

A pharma client partnered with ICON to support EU and US approval of a new diabetes therapy. ICON’s APS team sourced, labeled, and shipped comparator and study drugs for a complex phase 1 trial, helping meet the sponsor’s accelerated timeline.

A leading multinational pharmaceutical company partnered with ICON to conduct a phase 1 obesity study assessing the safety and tolerability of a new investigational oral amycretin therapy.

ICON was once again selected as a partner to conduct a phase 1 study in individuals who are overweight or have obesity, evaluating the safety and tolerability of a new subcutaneous GLP-1 and amylin peptide formulation.

A leading biotech company developing a groundbreaking non-opioid treatment for moderate-to-severe acute pain partnered with ICON to conduct a series of early-phase trials.

ICON's Accelerated Pharmaceuticals Solutions sourced, labeled, and globally distributed vitamin D for a phase 3 study, preventing delays and improving supply chain agility.

Analytical method development, validation, stability testing and compatibility assessments for a large pharma sponsor.

ICON conducted a multinational biosimilar phase 1 study for multiple sclerosis (MS). This trial was performed under high regulatory scrutiny and challenging pandemic conditions, with increased dosing targets requiring additional site activation.

ICON assisted in the recruitment of participants for a hot flash study that had a set of complex eligibility requirements.